Ly6C[superscript lo] monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy

Ly6C[superscript lo] monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy

Current anti-VEGF therapies for colorectal cancer (CRC) provide limited survival benefit, as tumors rapidly develop resistance to these agents. Here, we have uncovered an immunosuppressive role for nonclassical Ly6C lo monocytes that mediates resistance to anti-VEGFR2 treatment. We found that the ch...

Full description

Bibliographic Details
Main Authors: Jung, Keehoon (Author), Heishi, Takahiro (Author), Khan, Omar Fizal (Author), Kowalski, Piotr S (Author), Incio, Joao (Author), Rahbari, Nuh N. (Author), Chung, Euiheon (Author), Clark, Jeffrey W. (Author), Willett, Christopher G. (Author), Luster, Andrew D. (Author), Yun, Seok Hyun (Author), Langer, Robert S (Author), Anderson, Daniel Griffith (Author), Padera, Timothy P. (Author), Jain, Rakesh K. (Author), Fukumura, Dai (Author)
Other Authors: Massachusetts Institute of Technology. Department of Chemical Engineering (Contributor), Harvard University- (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: American Society for Clinical Investigation, 2019-08-14T15:56:28Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items